

Bruno Dubois

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11499075/publications.pdf>

Version: 2024-02-01

232
papers

53,453
citations

14124

69
h-index

2750

198
g-index

263
all docs

263
docs citations

263
times ranked

43670
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 270-279. | 0.4 | 7,498 |
| 2 | Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170. | 2.2 | 4,796 |
| 3 | MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601. | 2.2 | 4,389 |
| 4 | Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. <i>Lancet Neurology</i> , The, 2007, 6, 734-746. | 4.9 | 3,755 |
| 5 | Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , The, 2014, 13, 614-629. | 4.9 | 2,657 |
| 6 | Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1689-1707. | 2.2 | 2,497 |
| 7 | Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430. | 9.4 | 1,962 |
| 8 | A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 844-852. | 0.4 | 1,863 |
| 9 | Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323. | 0.4 | 1,318 |
| 10 | Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , The, 2016, 15, 455-532. | 4.9 | 1,242 |
| 11 | A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016, 87, 539-547. | 1.5 | 1,216 |
| 12 | Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007, 22, 41-47. | 2.2 | 1,097 |
| 13 | MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611. | 2.2 | 1,033 |
| 14 | Apathy and the Functional Anatomy of the Prefrontal Cortex-Basal Ganglia Circuits. <i>Cerebral Cortex</i> , 2006, 16, 916-928. | 1.6 | 1,025 |
| 15 | Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. <i>Movement Disorders</i> , 2007, 22, 2314-2324. | 2.2 | 885 |
| 16 | Rare coding variants in PLGG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384. | 9.4 | 783 |
| 17 | Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , The, 2017, 16, 661-676. | 4.9 | 464 |
| 18 | Amnesic MCI or prodromal Alzheimer's disease?. <i>Lancet Neurology</i> , The, 2004, 3, 246-248. | 4.9 | 459 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Consensus classification of posterior cortical atrophy. <i>Alzheimer's and Dementia</i> , 2017, 13, 870-884. | 0.4 | 423 |
| 20 | Support vector machine-based classification of Alzheimer's disease from whole-brain anatomical MRI. <i>Neuroradiology</i> , 2009, 51, 73-83. | 1.1 | 409 |
| 21 | A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 95. | 3.0 | 396 |
| 22 | Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology</i> , The, 2021, 20, 484-496. | 4.9 | 396 |
| 23 | Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 454-462. | 2.2 | 379 |
| 24 | Implementation of subjective cognitive decline criteria in research studies. <i>Alzheimer's and Dementia</i> , 2017, 13, 296-311. | 0.4 | 375 |
| 25 | Early and protective microglial activation in Alzheimer's disease: a prospective study using ¹⁸ F-DPA-714 PET imaging. <i>Brain</i> , 2016, 139, 1252-1264. | 3.7 | 365 |
| 26 | Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging. <i>NeuroImage</i> , 2009, 47, 1476-1486. | 2.1 | 354 |
| 27 | Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 58-69. | 0.4 | 352 |
| 28 | Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. <i>Neurobiology of Aging</i> , 2012, 33, 1203-1214.e2. | 1.5 | 346 |
| 29 | Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 617-631. | 1.2 | 330 |
| 30 | Drug development in Alzheimer's disease: the path to 2025. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 39. | 3.0 | 323 |
| 31 | On the path to 2025: understanding the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 60. | 3.0 | 316 |
| 32 | Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , The, 2020, 19, 951-962. | 4.9 | 254 |
| 33 | The Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease. <i>Focus (American Psychiatric Publishing)</i> , 2013, 11, 96-106. | 0.4 | 241 |
| 34 | Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328. | 1.3 | 215 |
| 35 | The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. <i>Nature Reviews Neuroscience</i> , 2022, 23, 53-66. | 4.9 | 203 |
| 36 | Targeting Prodromal Alzheimer Disease With Avagacestat. <i>JAMA Neurology</i> , 2015, 72, 1324. | 4.5 | 179 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 474. | 0.4 | 176 |
| 38 | Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 240-246. | 0.9 | 168 |
| 39 | The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2014, 10, 808-817. | 0.4 | 163 |
| 40 | The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. <i>Alzheimer's and Dementia</i> , 2015, 11, 111-125. | 0.4 | 162 |
| 41 | Cognitive and neuroimaging features and brain β -amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. <i>Lancet Neurology</i> , The, 2018, 17, 335-346. | 4.9 | 161 |
| 42 | Recommendations for the use of Serious Games in people with Alzheimer's Disease, related disorders and frailty. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 54. | 1.7 | 155 |
| 43 | What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. <i>Neurobiology of Aging</i> , 2020, 85, 58-73. | 1.5 | 150 |
| 44 | Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation. <i>Brain</i> , 2013, 136, 3474-3488. | 3.7 | 146 |
| 45 | Sensitivity to Semantic Cuing: An Index of Episodic Memory Dysfunction in Early Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 1999, 13, 38-46. | 0.6 | 142 |
| 46 | The Amnesic Syndrome of Hippocampal type in Alzheimer's Disease: An MRI Study. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 285-294. | 1.2 | 141 |
| 47 | Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis. <i>Annals of Neurology</i> , 2008, 64, S81-S92. | 2.8 | 122 |
| 48 | Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 764-775. | 0.4 | 122 |
| 49 | Similar amyloid- β burden in posterior cortical atrophy and Alzheimer's disease. <i>Brain</i> , 2011, 134, 2036-2043. | 3.7 | 121 |
| 50 | Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. <i>Neurobiology of Aging</i> , 2017, 59, 220.e1-220.e9. | 1.5 | 116 |
| 51 | A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 59-71. | 0.4 | 112 |
| 52 | Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease. <i>Brain</i> , 2018, 141, 1855-1870. | 3.7 | 111 |
| 53 | Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. <i>Biochemical Pharmacology</i> , 2014, 88, 426-449. | 2.0 | 105 |
| 54 | CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , 2015, 11, 1306-1315. | 0.4 | 104 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1041-1049. | 0.4 | 102 |
| 56 | Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228. | 4.5 | 97 |
| 57 | CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1253-1257. | 1.5 | 91 |
| 58 | Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A β ₄₂ , total tau, phosphorylated tau, NFL, neurogranin, and YKL40. <i>Alzheimer's and Dementia</i> , 2018, 14, 492-501. | 0.4 | 91 |
| 59 | A Critical Role for the Hippocampus in the Valuation of Imagined Outcomes. <i>PLoS Biology</i> , 2013, 11, e1001684. | 2.6 | 89 |
| 60 | Two Distinct Amnesic Profiles in Behavioral Variant Frontotemporal Dementia. <i>Biological Psychiatry</i> , 2014, 75, 582-588. | 0.7 | 86 |
| 61 | Brain perfusion SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease among patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2011, 32, 15-23. | 1.5 | 80 |
| 62 | Is Hippocampal Volume a Good Marker to Differentiate Alzheimer's Disease from Frontotemporal Dementia?. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 57-66. | 1.2 | 79 |
| 63 | Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 11706. | 1.6 | 79 |
| 64 | Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 130, 331-365. | 3.1 | 79 |
| 65 | Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. <i>Alzheimer's and Dementia</i> , 2018, 14, 1204-1215. | 0.4 | 79 |
| 66 | Free and Cued Selective Reminding Test accuracy for the differential diagnosis of Alzheimer's and neurodegenerative diseases: A large-scale biomarker-characterized monocenter cohort study (ClinAD). <i>Alzheimer's and Dementia</i> , 2017, 13, 913-923. | 0.4 | 75 |
| 67 | Detection of volume loss in hippocampal layers in Alzheimer's disease using 7T MRI: A feasibility study. <i>NeuroImage: Clinical</i> , 2014, 5, 341-348. | 1.4 | 74 |
| 68 | Early detection of Alzheimer's disease: new diagnostic criteria. <i>Dialogues in Clinical Neuroscience</i> , 2009, 11, 135-139. | 1.8 | 74 |
| 69 | International Work Group Criteria for the Diagnosis of Alzheimer Disease. <i>Medical Clinics of North America</i> , 2013, 97, 363-368. | 1.1 | 72 |
| 70 | Alzheimer's Disease Including Focal Presentations. <i>Seminars in Neurology</i> , 2019, 39, 213-226. | 0.5 | 72 |
| 71 | Temporal Order Memory Assessed during Spatiotemporal Navigation As a Behavioral Cognitive Marker for Differential Alzheimer's Disease Diagnosis. <i>Journal of Neuroscience</i> , 2012, 32, 1942-1952. | 1.7 | 66 |
| 72 | The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 27. | 3.0 | 66 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 83-105. | 1.4 | 64 |
| 74 | Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. <i>Alzheimer's and Dementia</i> , 2021, 17, 1528-1553. | 0.4 | 64 |
| 75 | Sensitivity and specificity of ventromedial prefrontal cortex tests in behavioral variant frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2013, 9, S84-94. | 0.4 | 63 |
| 76 | "Prodromal Alzheimer's disease": a more useful concept than mild cognitive impairment?. <i>Current Opinion in Neurology</i> , 2000, 13, 367-369. | 1.8 | 59 |
| 77 | Social Cognition Deficits: The Key to Discriminate Behavioral Variant Frontotemporal Dementia from Alzheimer's Disease Regardless of Amnesia?. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 1065-1074. | 1.2 | 59 |
| 78 | How Preserved is Emotion Recognition in Alzheimer Disease Compared With Behavioral Variant Frontotemporal Dementia?. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 154-157. | 0.6 | 59 |
| 79 | Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. <i>Alzheimer's and Dementia</i> , 2017, 13, 454-467. | 0.4 | 58 |
| 80 | The Emergence of a New Conceptual Framework for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1059-1066. | 1.2 | 56 |
| 81 | The AD-CSF-Index Discriminates Alzheimer's Disease Patients from Healthy Controls: A Validation Study. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 67-77. | 1.2 | 53 |
| 82 | Clinical and Research Diagnostic Criteria for Alzheimer's Disease. <i>Neuroimaging Clinics of North America</i> , 2012, 22, 23-32. | 0.5 | 51 |
| 83 | Clinical validation of movement disorder society's recommended diagnostic criteria for Parkinson's disease with dementia. <i>Movement Disorders</i> , 2012, 27, 248-253. | 2.2 | 51 |
| 84 | Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 153-166. | 1.5 | 49 |
| 85 | Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , 2019, 83, 42-53. | 1.5 | 48 |
| 86 | Frontal lobe neurology and the creative mind. <i>Frontiers in Psychology</i> , 2014, 5, 761. | 1.1 | 47 |
| 87 | Direct current stimulation over the anterior temporal areas boosts semantic processing in primary progressive aphasia. <i>Annals of Neurology</i> , 2016, 80, 693-707. | 2.8 | 47 |
| 88 | Determinants of theory of mind performance in Alzheimer's disease: A data-mining study. <i>Cortex</i> , 2017, 88, 8-18. | 1.1 | 47 |
| 89 | Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. <i>Neurochemistry International</i> , 2017, 108, 355-360. | 1.9 | 46 |
| 90 | Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 67. | 3.0 | 45 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Association of cerebrospinal fluid τ -synuclein with total and phospho τ protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2018, 14, 1623-1631. | 0.4 | 45 |
| 92 | Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016, 31, 1623-1627. | 2.2 | 43 |
| 93 | Functional Connectivity of Ventral and Dorsal Visual Streams in Posterior Cortical Atrophy. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1119-1130. | 1.2 | 43 |
| 94 | Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 940-950. | 0.4 | 43 |
| 95 | Sulcal morphology as a new imaging marker for the diagnosis of early onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2932-2939. | 1.5 | 39 |
| 96 | Two-level diagnostic classification using cerebrospinal fluid YKL40 in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 993-1003. | 0.4 | 39 |
| 97 | The biomarker-based diagnosis of Alzheimer's disease. 2 lessons from oncology. <i>Neurobiology of Aging</i> , 2017, 52, 141-152. | 1.5 | 38 |
| 98 | Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services part 4 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 171. | 3.0 | 37 |
| 99 | Toward noninvasive brain stimulation 2.0 in Alzheimer's disease. <i>Ageing Research Reviews</i> , 2022, 75, 101555. | 5.0 | 37 |
| 100 | Parkinson's disease dementia can be easily detected in routine clinical practice. <i>Movement Disorders</i> , 2010, 25, 2769-2776. | 2.2 | 36 |
| 101 | Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 18. | 3.0 | 36 |
| 102 | Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1327-1334. | 1.2 | 35 |
| 103 | Effectiveness of Florbetapir PET Imaging in Changing Patient Management. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 129-143. | 0.7 | 35 |
| 104 | Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services part 2 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 169. | 3.0 | 35 |
| 105 | Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S171-S191. | 1.2 | 34 |
| 106 | Relationships between objective sleep parameters and brain amyloid load in subjects at risk for Alzheimer's disease: the INSIGHT-preAD Study. <i>Sleep</i> , 2019, 42, . | 0.6 | 32 |
| 107 | Disrupted white matter structural networks in healthy older adult APOE ϵ 4 carriers: An international multicenter DTI study. <i>Neuroscience</i> , 2017, 357, 119-133. | 1.1 | 31 |
| 108 | Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. <i>Journal of Neurology</i> , 2014, 261, 1234-1243. | 1.8 | 30 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid- β^2 Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints. <i>Radiology</i> , 2019, 290, 167-176. | 3.6 | 30 |
| 110 | Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. <i>Neurobiology of Aging</i> , 2020, 90, 43-59. | 1.5 | 30 |
| 111 | Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease with an implantable ultrasound device. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 40. | 3.0 | 30 |
| 112 | Frontal presentation of Alzheimer's disease: A series of patients with biological evidence by CSF biomarkers. <i>Dementia E Neuropsychologia</i> , 2013, 7, 66-74. | 0.3 | 29 |
| 113 | Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 793-804. | 1.2 | 28 |
| 114 | Why do patients with neurodegenerative frontal syndrome fail to answer: "In what way are an orange and a banana alike?" <i>Brain</i> , 2015, 138, 456-471. | 3.7 | 28 |
| 115 | Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, 503-512. | 0.3 | 27 |
| 116 | Cognitive and behavioural inhibition deficits in neurodegenerative dementias. <i>Cortex</i> , 2020, 131, 265-283. | 1.1 | 27 |
| 117 | Clinical Investigations in Primary Care. <i>Frontiers of Neurology and Neuroscience</i> , 2009, 24, 1-11. | 3.0 | 26 |
| 118 | Fully Automated Atlas-Based Hippocampus Volumetry for Clinical Routine: Validation in Subjects with Mild Cognitive Impairment from the ADNI Cohort. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 199-209. | 1.2 | 25 |
| 119 | Brain $A\beta$ load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2019, 15, 1274-1285. | 0.4 | 25 |
| 120 | Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 15. | 3.0 | 24 |
| 121 | Distinct brain perfusion pattern associated with CSF biomarkers profile in primary progressive aphasia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 695-698. | 0.9 | 23 |
| 122 | World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015, 19, 2-7. | 1.2 | 23 |
| 123 | Neural correlates of episodic memory in the Memento cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 224-233. | 1.8 | 23 |
| 124 | Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 147. | 3.0 | 23 |
| 125 | Primary Progressive Aphasia Associated With <i>GRN</i> Mutations. <i>Neurology</i> , 2021, 97, e88-e102. | 1.5 | 23 |
| 126 | Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 589-593. | 3.3 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Low Prevalence and Clinical Effect of Vascular Risk Factors in Early-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1045-1054. | 1.2 | 22 |
| 128 | Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845. | 0.4 | 22 |
| 129 | Revised research diagnostic criteria for Alzheimer's disease. <i>Lancet Neurology</i> , The, 2008, 7, 668-670. | 4.9 | 21 |
| 130 | Neuroimaging in dementias. <i>Current Opinion in Psychiatry</i> , 2012, 25, 473-479. | 3.1 | 21 |
| 131 | Atrophy, metabolism and cognition in the posterior cortical atrophy spectrum based on Alzheimer's disease cerebrospinal fluid biomarkers. <i>NeuroImage: Clinical</i> , 2018, 20, 1018-1025. | 1.4 | 21 |
| 132 | In vivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 93, 98-108. | 1.5 | 21 |
| 133 | Judgments about moral responsibility and determinism in patients with behavioural variant of frontotemporal dementia: Still compatibilists. <i>Consciousness and Cognition</i> , 2012, 21, 851-864. | 0.8 | 20 |
| 134 | Amyloidosis and neurodegeneration result in distinct structural connectivity patterns in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2017, 55, 177-189. | 1.5 | 20 |
| 135 | Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. <i>Neurology</i> , 2020, 94, e30-e41. | 1.5 | 20 |
| 136 | European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. <i>European Journal of Neurology</i> , 2021, 28, 2147-2155. | 1.7 | 20 |
| 137 | Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 867-873. | 1.2 | 19 |
| 138 | No association of cortical amyloid load and EEG connectivity in older people with subjective memory complaints. <i>NeuroImage: Clinical</i> , 2018, 17, 435-443. | 1.4 | 19 |
| 139 | Accuracy of MRI Classification Algorithms in a Tertiary Memory Center Clinical Routine Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1157-1166. | 1.2 | 19 |
| 140 | Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 324-333. | 1.3 | 19 |
| 141 | Biological markers of Alzheimer's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 227-231. | 0.3 | 18 |
| 142 | Influence of Lewy Pathology on Alzheimer's Disease Phenotype: A Retrospective Clinico-Pathological Study. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1317-1323. | 1.2 | 18 |
| 143 | Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 129. | 3.0 | 18 |
| 144 | Association of plasma YKL-40 with brain amyloid- β^2 levels, memory performance, and sex in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 96, 22-32. | 1.5 | 18 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Radiological classification of dementia from anatomical MRI assisted by machine learning-derived maps. <i>Journal of Neuroradiology</i> , 2021, 48, 412-418. | 0.6 | 18 |
| 146 | A machine learning approach to screen for preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 105, 205-216. | 1.5 | 18 |
| 147 | AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials. <i>Alzheimer's and Dementia</i> , 2011, 7, e109-17. | 0.4 | 17 |
| 148 | So Close Yet So Far: Executive Contribution to Memory Processing in Behavioral Variant Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1005-1014. | 1.2 | 17 |
| 149 | Awareness of Cognitive Decline in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 697234. | 1.7 | 17 |
| 150 | Which Episodic Memory Performance is Associated with Alzheimer's Disease Biomarkers in Elderly Cognitive Complainers? Evidence from a Longitudinal Observational Study with Four Episodic Memory Tests (Insight-PreAD). <i>Journal of Alzheimer's Disease</i> , 2019, 70, 811-824. | 1.2 | 16 |
| 151 | How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years. <i>BMJ Open</i> , 2019, 9, e029663. | 0.8 | 16 |
| 152 | β -Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 130. | 3.0 | 16 |
| 153 | Does amnesia specifically predict Alzheimer's pathology? A neuropathological study. <i>Neurobiology of Aging</i> , 2020, 95, 123-130. | 1.5 | 15 |
| 154 | The utility of the new research diagnostic criteria for Alzheimer's disease. <i>International Psychogeriatrics</i> , 2013, 25, 175-177. | 0.6 | 14 |
| 155 | Language boosting by transcranial stimulation in progressive supranuclear palsy. <i>Neurology</i> , 2019, 93, e537-e547. | 1.5 | 14 |
| 156 | Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasia. <i>Neurology</i> , 2018, 90, e1057-e1065. | 1.5 | 13 |
| 157 | MiRNA-15b and miRNA-125b are associated with regional β -PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints. <i>Translational Psychiatry</i> , 2021, 11, 78. | 2.4 | 13 |
| 158 | Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer's disease: A randomized, placebo-controlled, phase 3 clinical trial (MINDSET). <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12136. | 1.8 | 12 |
| 159 | A Reliable and Rapid Language Tool for the Diagnosis, Classification, and Follow-Up of Primary Progressive Aphasia Variants. <i>Frontiers in Neurology</i> , 2020, 11, 571657. | 1.1 | 11 |
| 160 | A mosquito bites and a butterfly flies: A specific response type of frontal patients in a similarity task. <i>Neuropsychologia</i> , 2018, 117, 371-378. | 0.7 | 10 |
| 161 | Moral Emotions in Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 887-896. | 1.2 | 10 |
| 162 | Plasma β -secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2021, 17, 629-640. | 0.4 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Effect of Six Months of Treatment with V0191 in Patients with Suspected Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 527-535. | 1.2 | 9 |
| 164 | Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 455-461. | 0.4 | 9 |
| 165 | Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 553-562. | 1.8 | 8 |
| 166 | Cognition, behavior and the frontal lobes. <i>International Psychogeriatrics</i> , 2004, 16, 379-387. | 0.6 | 7 |
| 167 | New lexicon and criteria for the diagnosis of Alzheimer's disease – Authors' reply. <i>Lancet Neurology</i> , The, 2011, 10, 300-301. | 4.9 | 7 |
| 168 | Behavioral variant frontotemporal dementia patients do not succumb to the Allais paradox. <i>Frontiers in Neuroscience</i> , 2014, 8, 287. | 1.4 | 7 |
| 169 | Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. <i>Movement Disorders</i> , 2014, 29, 1252-1257. | 2.2 | 7 |
| 170 | Altered age-linked regulation of plasma DYRK1A in elderly cognitive complainers (INSIGHT-preAD study) with high brain amyloid load. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12046. | 1.8 | 7 |
| 171 | Relevance of the Evaluation Criteria Used in Clinical Trials for Alzheimer's Disease. <i>Therapie</i> , 2009, 64, 145-148. | 0.6 | 5 |
| 172 | Parietal Involvement in the Semantic Variant of Primary Progressive Aphasia with Alzheimer's Disease Cerebrospinal Fluid Profile. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 271-280. | 1.2 | 5 |
| 173 | Association of plasma A β 40/A β 42 ratio and brain A β accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 107, 57-69. | 1.5 | 5 |
| 174 | Magnetic resonance imaging-based hippocampus volume for prediction of dementia in mild cognitive impairment: Why does the measurement method matter so little?. <i>Alzheimer's and Dementia</i> , 2018, 14, 976-978. | 0.4 | 4 |
| 175 | Association of brain network dynamics with plasma biomarkers in subjective memory complainers. <i>Neurobiology of Aging</i> , 2020, 88, 83-90. | 1.5 | 4 |
| 176 | Overview of dominantly inherited AD and top-line DIAN-TU results of solanezumab and gantenerumab. <i>Alzheimer's and Dementia</i> , 2020, 16, e041129. | 0.4 | 4 |
| 177 | Are PSP patients included in clinical trials representative of the general PSP population?. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 202-206. | 1.1 | 3 |
| 178 | Does surface dyslexia/dysgraphia relate to semantic deficits in the semantic variant of primary progressive aphasia?. <i>Neuropsychologia</i> , 2019, 135, 107241. | 0.7 | 3 |
| 179 | Solanezumab in-depth outcomes. <i>Alzheimer's and Dementia</i> , 2020, 16, e038028. | 0.4 | 3 |
| 180 | Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 748198. | 1.7 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Clinical diagnosis of Alzheimer's disease: Recommendations of the International Working Group (IWG). <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.4 | 3 |
| 182 | Alzheimer's Disease Diagnosis Relies on a Twofold Clinical-Biological Algorithm: Three Memory Clinic Case Reports. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 577-583. | 1.2 | 2 |
| 183 | COGEVIS: A New Scale to Evaluate Cognition in Patients with Visual Deficiency. <i>Behavioural Neurology</i> , 2018, 2018, 1-7. | 1.1 | 2 |
| 184 | Gantenerumab in-depth outcomes. <i>Alzheimer's and Dementia</i> , 2020, 16, e038049. | 0.4 | 2 |
| 185 | Alzheimer's disease brain atrophy subtypes are associated with incident dementia in subjective cognitive complaint and mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e039861. | 0.4 | 2 |
| 186 | Aging and sex impact plasma NFL and τ trajectories in individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041792. | 0.4 | 2 |
| 187 | Biomarkers for the Early Stages of Clinical Development in Alzheimer's Disease. <i>Therapie</i> , 2010, 65, 285-290. | 0.6 | 1 |
| 188 | P3218: NOVEL ALZHEIMER'S DISEASE BIOMARKER-GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VALUE OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: $A\beta_{1-42}$, TOTAL τ , PHOSPHORYLATED τ , NFL, NEUROGRANIN, AND YKL40. <i>Alzheimer's and Dementia</i> , 2018, 14, P1154. | 0.4 | 1 |
| 189 | P1313: THE EATING BEHAVIOR INVENTORY (EBI): A 30-ITEM CLINICAL TOOL TO DISTINGUISH FRONTOTEMPORAL DEMENTIA FROM BIPOLAR DISORDER. <i>Alzheimer's and Dementia</i> , 2018, 14, P411. | 0.4 | 1 |
| 190 | EEG: A valuable tool to screen for neurodegeneration in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e039696. | 0.4 | 1 |
| 191 | Recommendations of the International Working Group for the clinical diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.4 | 1 |
| 192 | S2-02-01: Concepts of Preclinical Dementias. , 2011, 7, S280-S280. | | 0 |
| 193 | Subjective cognitive complaint. , 0, , 6-12. | | 0 |
| 194 | Ask The Experts: New diagnostic criteria for Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2012, 2, 153-157. | 1.2 | 0 |
| 195 | [P1301]: THE MINI EATING BEHAVIOR INVENTORY (MINI EBI): A 10-ITEM CLINICAL TOOL FOR THE EARLY DIAGNOSIS OF FRONTOTEMPORAL DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P368. | 0.4 | 0 |
| 196 | [P2412]: A FUNCTIONAL RESTING STATE STUDY OF BASAL FOREBRAIN FUNCTIONAL CONNECTIVITY IN ASYMPTOMATIC AT-RISK INDIVIDUALS FOR AD: THE INSIGHT-PRE AD STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P790. | 0.4 | 0 |
| 197 | [ICP152]: ASSOCIATION OF CORTICAL AMYLOID LOAD WITH RESTING STATE EEG FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS FROM THE INSIGHT-PRE AD STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P114. | 0.4 | 0 |
| 198 | [P1388]: DIFFERENT STRUCTURAL CONNECTIVITY PATTERNS IN MILD COGNITIVE IMPAIRMENT STRATIFIED BY AMYLOID AND NEURODEGENERATION BIOMARKERS. <i>Alzheimer's and Dementia</i> , 2017, 13, P414. | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | [P1â€“438]: SPONTANEOUS LOWâ€“FREQUENCY BOLD SIGNAL FLUCTUATIONS IN OLDER SUBJECTIVE MEMORY COMPLAINERS WITH OR WITHOUT BRAIN AMYLOIDOSIS: THE INSIGHTâ€“PREâ€“AD STUDY. Alzheimer's and Dementia, 2017, 13, P450. | 0.4 | 0 |
| 200 | [P1â€“441]: ASSOCIATION OF CORTICAL AMYLOID LOAD WITH RESTINGâ€“STATE EEG FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS FROM THE INSIGHTâ€“PREâ€“AD STUDY. Alzheimer's and Dementia, 2017, 13, P451. | 0.4 | 0 |
| 201 | [P2â€“028]: EFFECT OF CHOLINESTERASE INHIBITORS ON BRAIN CHOLINERGIC STRUCTURES. Alzheimer's and Dementia, 2017, 13, P615. | 0.4 | 0 |
| 202 | [P4â€“236]: COMPARISON OF BRAIN MORPHOLOGY BETWEEN TWO DATABASES OF ELDERLY COGNITIVELY INTACT INDIVIDUALS FOR THE VALIDATION OF HIPPOCAMPAL VOLUME NORMATIVE DATA IN THE FRENCH INSIGHTâ€“PRE AD COHORT. Alzheimer's and Dementia, 2017, 13, P1364. | 0.4 | 0 |
| 203 | P4â€“072: INCREASED PLASMA BACE1 CONCENTRATIONS IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS: CORRELATION WITH PLASMA NFL. Alzheimer's and Dementia, 2018, 14, P1461. | 0.4 | 0 |
| 204 | P1â€“627: AMYLOID BURDEN IMPACTS EVERYDAY FUNCTIONING INDEPENDENT OF COGNITION AND AWARENESS IN SUBJECTIVE COGNITIVE DECLINE: FINDINGS FROM THE INSIGHT PREâ€“AD COHORT. Alzheimer's and Dementia, 2018, 14, P581. | 0.4 | 0 |
| 205 | P3â€“411: CLINICAL SIGNIFICANCE OF INâ€“VIVO STAGING OF REGIONAL AMYLOID DEPOSITION IN SUBJECTIVE MEMORY COMPLAINERS. Alzheimer's and Dementia, 2018, 14, P1262. | 0.4 | 0 |
| 206 | P3â€“279: COGNITION AND LOW VISION: COGEVIS. Alzheimer's and Dementia, 2018, 14, P1185. | 0.4 | 0 |
| 207 | P2â€“237: ASSOCIATION OF CSF ALPHAâ€“SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P762. | 0.4 | 0 |
| 208 | O4â€“07â€“04: INCREASED RESILIENCE TO ALZHEIMER'S DISEASE PATHOPHYSIOLOGY IN MEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO WOMEN. Alzheimer's and Dementia, 2018, 14, P1419. | 0.4 | 0 |
| 209 | O3â€“09â€“02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOIDâ€“PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P1036. | 0.4 | 0 |
| 210 | P4â€“186: INNOVATIVE BIOMARKERâ€“GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER'S DISEASE, DEMENTIA. Alzheimer's and Dementia, 2018, 14, P1510. | 0.4 | 0 |
| 211 | P2â€“246: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKLâ€“40 CONCENTRATIONS IN AMYLOIDâ€“PET POSITIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P767. | 0.4 | 0 |
| 212 | P2â€“249: CORRELATIONS AND ALTERED LONGITUDINAL DYNAMICS OF PLASMA BACE1 AND NFL CONCENTRATIONS IN INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. Alzheimer's and Dementia, 2018, 14, P768. | 0.4 | 0 |
| 213 | P2â€“277: CORTICAL SULCI WIDTH AND INCIDENT DEMENTIA IN OUTPATIENTS ATTENDING FRENCH MEMORY CLINICS: THE MEMENTO COHORT. Alzheimer's and Dementia, 2018, 14, P784. | 0.4 | 0 |
| 214 | P4â€“088: EVOLUTION OF THE AWARENESS OF COGNITIVE DECLINE INDEX OVER 24 MONTHS IN PRECLINICAL ALZHEIMER'S DISEASE IS ASSOCIATED TO BASELINE BRAIN AMYLOID LOAD. Alzheimer's and Dementia, 2018, 14, P1469. | 0.4 | 0 |
| 215 | Reduced awareness of cognitive decline is associated with brain amyloid load in asymptomatic elderly individuals at risk for AD: A longitudinal study. Alzheimer's and Dementia, 2020, 16, e037138. | 0.4 | 0 |
| 216 | A specific pattern of memory errors in asymptomatic atâ€“risk for AD. Alzheimer's and Dementia, 2020, 16, e037385. | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 217 | In vivo characterization of progressive amnesic syndrome due to suspected neurodegenerative non-Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e039587. | 0.4 | 0 |
| 218 | Association of plasma YKL40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020, 16, e041753. | 0.4 | 0 |
| 219 | Pathways involved in the relationship between resilience and cognitive function: The Memento cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e042674. | 0.4 | 0 |
| 220 | Predicting factors of cognitive progression in preclinical AD: A five-year follow-up of the insight study. <i>Alzheimer's and Dementia</i> , 2020, 16, e042896. | 0.4 | 0 |
| 221 | Multimodal screening for neurodegeneration in preclinical Alzheimer's disease using EEG, APOE4 genotype, neuropsychological and MRI data. <i>Alzheimer's and Dementia</i> , 2020, 16, e044027. | 0.4 | 0 |
| 222 | Current status and quantitative results of the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044711. | 0.4 | 0 |
| 223 | Cortical microstructural changes and amyloid beta burden in cognitively normal subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020, 16, e046014. | 0.4 | 0 |
| 224 | Sex differences in cortical microstructural changes in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046105. | 0.4 | 0 |
| 225 | Impact of the IWG/Dubois Criteria for Alzheimer's Disease in Imaging Studies. , 2014, , 309-322. | | 0 |
| 226 | Que penser de l'approche médicamenteuse préventive de la maladie d'Alzheimer ?. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 679-690. | 0.0 | 0 |
| 227 | lncRNAs as a novel source of diagnostic applications for early Alzheimer's disease and other dementia types. <i>Alzheimer's and Dementia</i> , 2020, 16, e039788. | 0.4 | 0 |
| 228 | Enlightening behavioral disturbances in myotonic dystrophy type 1 through neuropsychology and imaging correlations: Insights from the frontal and temporal lobe functions. <i>Alzheimer's and Dementia</i> , 2020, 16, e043114. | 0.4 | 0 |
| 229 | Impact of the New Conceptual Framework of Alzheimer's Disease in Imaging Studies. , 2021, , 427-451. | | 0 |
| 230 | Subtle postoperative cognitive disorder in preclinical Alzheimer's disease. <i>Experimental Gerontology</i> , 2022, 161, 111715. | 1.2 | 0 |
| 231 | Why don't Alzheimer's disease patients know that they forget?. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.4 | 0 |
| 232 | Education and brain amyloid load act on temporal lobe function in individual with subjective memory complaint: An EEG-fMRI study. <i>Alzheimer's and Dementia</i> , 2021, 17, . | 0.4 | 0 |